The p38 pathway: from biology to cancer therapy

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Martínez Limón, Adrián
• dc.contributor.author Joaquin i Caudet, Manel
• dc.contributor.author Caballero, María
• dc.contributor.author Posas Garriga, Francesc
• dc.contributor.author Nadal Clanchet, Eulàlia de
• dc.date.accessioned 2020-04-20T07:35:02Z
• dc.date.available 2020-04-20T07:35:02Z
• dc.date.issued 2020
• dc.description.abstract The p38 MAPK pathway is well known for its role in transducing stress signals from the environment. Many key players and regulatory mechanisms of this signaling cascade have been described to some extent. Nevertheless, p38 participates in a broad range of cellular activities, for many of which detailed molecular pictures are still lacking. Originally described as a tumor-suppressor kinase for its inhibitory role in RAS-dependent transformation, p38 can also function as a tumor promoter, as demonstrated by extensive experimental data. This finding has prompted the development of specific inhibitors that have been used in clinical trials to treat several human malignancies, although without much success to date. However, elucidating critical aspects of p38 biology, such as isoform-specific functions or its apparent dual nature during tumorigenesis, might open up new possibilities for therapy with unexpected potential. In this review, we provide an extensive description of the main biological functions of p38 and focus on recent studies that have addressed its role in cancer. Furthermore, we provide an updated overview of therapeutic strategies targeting p38 in cancer and promising alternatives currently being explored.
• dc.description.sponsorship This work was supported by grants from the Spanish Ministry of Economy and Competitiveness (BFU2017-85152-P and FEDER to E.d.N and PGC2018-094136-B-I00 and FEDER to F.P.], the AECC Foundation [PROYE18010POSA to F.P.) and the Catalan Government (2017 SGR 799 to E.d.N and F.P.). F.P. is a recipient of an ICREA Acadèmia award (Catalan Government). We gratefully acknowledge institutional funding from the Spanish Ministry of Economy, Industry and Competitiveness (MINECO) through the Centres of Excellence Severo Ochoa award, from the CERCA Programme of the Catalan Government, and from “Unidad de Excelencia María de Maeztu,” funded by the AEI (CEX2018-000792-M).
• dc.format.mimetype application/pdf
• dc.identifier.citation Martínez-Limón A, Joaquin M, Caballero M, Posas F, de Nadal E. The p38 pathway: from biology to cancer therapy. Int J Mol Sci. 2020; 21(6). pii: E1913. DOI: 10.3390/ijms21061913
• dc.identifier.doi http://dx.doi.org/10.3390/ijms21061913
• dc.identifier.issn 1422-0067
• dc.identifier.uri http://hdl.handle.net/10230/44274
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Int J Mol Sci. 2020; 21(6). pii: E1913
• dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/BFU2017-85152-P
• dc.rights © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword SAPK
• dc.subject.keyword Cancer treatment
• dc.subject.keyword Oncogenicity
• dc.subject.keyword p38 MAPK
• dc.subject.keyword Phosphorylation
• dc.subject.keyword Tumor suppressor
• dc.title The p38 pathway: from biology to cancer therapy
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion